Pancreatic cancer drug shows 41% response rate in clinical trial

Verastem Oncology (NASDAQ:VSTM) reported significant clinical data for its KRAS G12D inhibitor, VS-7375, demonstrating a 41% overall response rate and 96.7% disease control rate in heavily pre-treated pancreatic cancer patients at ESMO 2025, addressing a critical unmet need given the lack of FDA-approved therapies. The company, whose stock has surged over 211% in the past year, also saw its partner present promising 68.8% ORR data for the same drug in non-small cell lung cancer. Financially, Verastem posted a Q2 2025 non-GAAP net loss of $41.4 million on $2.1 million in revenue, but strengthened its balance sheet with a $75 million private placement, leading to continued positive analyst sentiment despite some price target adjustments.

Analysis

Verastem Oncology (NASDAQ:VSTM) reported compelling clinical data for its KRAS G12D inhibitor, VS-7375, demonstrating a 41% overall response rate and 96.7% disease control rate in 59 heavily pre-treated pancreatic cancer patients. This is critical as no FDA-approved therapies specifically target KRAS G12D mutations, which are linked to poorer outcomes in 37% of pancreatic cancers. The drug also demonstrated a manageable safety profile, with only a 3% discontinuation rate due to adverse events.

Further positive data emerged from partner GenFleet Therapeutics, reporting a 68.8% overall response rate for the inhibitor in non-small cell lung cancer patients. Despite a Q2 2025 non-GAAP net loss of $41.4 million on $2.1 million in revenue, Verastem strengthened its financial position with a $75 million private placement. The company maintains a strong liquidity position, evidenced by a 3.46x current ratio and more cash than debt, supporting its drug pipeline.

Verastem's stock has surged over 211% in the past year, reflecting market enthusiasm for its clinical progress. Analyst sentiment remains largely positive, with BTIG reiterating a Buy rating and Mizuho maintaining an Outperform rating despite a price target adjustment from $16.00 to $14.00 due to dilution. The upcoming November 6 earnings report will offer further insights into financial performance and pipeline advancement.

Key Decisions for Investors

• Monitor ongoing clinical trial results for VS-7375, particularly for expansion into other solid tumors, as this could significantly broaden market opportunity
• Evaluate the Q3 earnings report on November 6 for insights into cash burn and financial runway post-$75 million private placement
• Consider the long-term growth potential driven by strong clinical data in an unmet medical need, while acknowledging the high-risk nature of biotech investments and potential for future dilution